TEST:

OncoReveal™ Solid Tumor Panel

"Pillar Biosciences, Inc...announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619)."

"Beckman Coulter Life Sciences...announces a collaboration agreement with Pillar Biosciences, which develops and distributes IVD & RUO NGS testing solutions based on their proprietary SLIMamp® technology to help localize patient testing and optimize the selection of precision therapies for cancer patients...The application development partnership is initially focused on five commercially-available, solid tumor liquid biopsy and hematology panels from Pillar Biosciences..."

The automated Pillar ORST22 assay on Biomek NGeniuS system produced high-quality and robust results with minimal hands-on time and human intervention. Together with the easyto-use setup, it could substantially reduce the lab operation burden.

This study demonstrates the advantages of NGS Library Preparation kit using Pillar’s SLIMamp technology on clinical samples of low quality/quantity. In combination with the post-sequencing QC metric, which we developed during this study, SLIMamp kits can be used for clinical testing on a large proportion of the most challenging clinical samples, which otherwise would go untested.

11 samples were deemed to be unreportable and the sequencing data were likely dominated by artefacts. A novel post-sequencing QC metric was developed which can discriminate between clinically reportable and unreportable samples.

We demonstrated that the SLIMamp technology is able to successfully test most samples that cannot be tested by CGP or, potentially, conventional amplicon sequencing methods. SLIMamp kits, in combination with our novel post-sequencing QC metric, enable clinical testing for predictive biomarkers on a large proportion of the most challenging clinical samples which would otherwise go untested.

"Pillar Biosciences...announced that its abstract, 'Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology', has been published online in the Journal of Clinical Oncology, in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting...The study showed that oncoReveal™ Solid Tumor Panel with Pillar Biosciences’ proprietary SLIMamp® technology, was able to generate reliable, interpretable results for almost all of the samples that had failed pre-analytical QC for WES."

In this study, we showed that the Pillar Biosciences oncoReveal Solid Tumor Panel, which uses SLIMam technology, was able to generate reliable, interpretable results for 94% of samples that failed pre-analytical QC for WES, substantiating Pillar’s claim.